Table 3.
Laboratory results for all participants.
| Characteristic | cART-naïve (n = 20)a | cART-treated inadequate responders (n = 20)a | cART-treated responders (n = 20)a | Noninfected controls (n = 20)a | Overall P value | |||
|---|---|---|---|---|---|---|---|---|
| IL-37 mRNA:U6 ratio per 106 PBMCs unstimulated (SD) | 0.080 (0.05) | ** | 0.129 (0.10) | **** | 0.134 (0.12) | **** | 0.033 (0.03) | <0.0001 |
| IL-37 mRNA:U6 ratio per 106 PBMCs stimulated with RPMI for 24 h (SD) | 0.559 (0.45) | **** | 0.815 (0.38) | **** | 0.658 (0.34) | **** | 0.140 (0.11) | <0.0001 |
| IL-37 mRNA:U6 ratio per 106 PBMCs stimulated with LPS 24h (SD) | 0.759 (0.62) | ** | 1.372 (0.76) | **** | 1.198 (1.40) | **** | 0.210 (0.13) | <0.0001 |
| sCD14 plasma, 106 pg/mL (SD) | 4.27 (1.05) | ns | 4.91 (1.07) | * | 3.65 (0.80) | ns | 2.62 (0.35) | 0.03 |
| sCD163 plasma μg/mL (SD) | 2.78 (1.30) | *** | 2.25 (0.91) | * | 1.66 (0.55) | ns | 1.52 (0.44) | <0.0001 |
| hsIL-6 plasma, pg/mL (SD) | 3.65 (2.94) | ns | 3.13 (2.79) | ns | 3.43 (2.90) | ns | 2.35 (2.49) | 0.17 |
| CD38 positive CD4+ T cells (SD) | 16.9 (6.5) | ns | 15.3 (9.1) | ns | 10.9 (4.3) | ns | 11.6 (4.9) | 0.01 |
| CD38 positive CD8+ T cells (SD) | 21.3 (10.6) | **** | 7.0 (6.0) | ns | 3.1 (1.9) | ns | 3.7 (2.0) | <0.0001 |
| Total viral reservoir, HIV-DNA per 106 PBMCs (SD) | — | — | 424.9 (623) | — | 582.6 (976) | — | — | 0.95 |
SD, standard deviation.
a
ANOVA with multiple comparisons analysis. Asterisks (*) correspond to the level of significance in relation to noninfected controls: *: p ≤ 0.05; **: p ≤ 0.01; ***: p ≤ 0.001; ****: p ≤ 0.0001; ns: p > 0.05. Right column corresponds to the overall comparison.